3Vel(lzquez-Ch6vez FJ,Tapia-Gonz61ez Mde L, Gonz(llez-Bdrcena D. Use- fulness of eabergoline in patients with prolactinemia and resistant or intol- erant to bromocriptine. Cir,2009,77 : 173-177.
4Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary ,2009 : 12:96-104.
5Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. Journal of Cellular Biochemistry ,2009,107,677-685.
6The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J].Hum Reprod,2004,19(1):41-47.
7Yildiz BO,Knochenhaner ES,Azziz R.Impact of obesity on the risk for polycystic ovary syndrome[J].J Clin Endocrinol Metab,2008,93(1):162-168.
8Espinos-Gomez JJ,Corcoy R,Calaf J.Prevalence and predictors of abnormal glucose metabolism in mediterranean women with polycystic ovary syndrome[J].Gynecol Endocrinol,2009,25(3):199-204.
9Altuntas CZ,Johnson JM,Tuohy VK.Autoimmune targeted disruption of the pituitary-ovarian axis causes premature ovarian failure[J].Immune,2006,177(3):1996-1998.
10Shelling AN.Premature ovarian failure 2010 Society for Reproduction and Fertility[J].Reproduction,2010,140(5):633-641.
